Optimization of atorvastatin and quercetin-loaded solid lipid nanoparticles using Box-Behnken design.

Nanomedicine (London, England) Pub Date : 2024-07-14 Epub Date: 2024-07-16 DOI:10.1080/17435889.2024.2364585
Dimple S Lalchandani, Laltanpuii Chenkual, Kailas Sonpasare, Bishal Rajdev, Vgm Naidu, Naveen Chella, Pawan Kumar Porwal
{"title":"Optimization of atorvastatin and quercetin-loaded solid lipid nanoparticles using Box-Behnken design.","authors":"Dimple S Lalchandani, Laltanpuii Chenkual, Kailas Sonpasare, Bishal Rajdev, Vgm Naidu, Naveen Chella, Pawan Kumar Porwal","doi":"10.1080/17435889.2024.2364585","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> The study explores the synergistic potential of atorvastatin (ATR) and quercetin (QUER)- loaded solid lipid nanoparticles (SLN) in combating breast cancer. <b>Materials & methods:</b> SLNs were synthesized using a high-shear homogenization method and optimized using Box-Behnken design. The SLNs were characterized and evaluated for their <i>in vitro</i> anticancer activity. <b>Results:</b> The optimized SLN exhibited narrow size distribution (PDI = 0.338 ± 0.034), a particle size of 72.5 ± 6.5 nm, higher entrapment efficiency (<90%), sustained release and spherical surface particles. The <i>in vitro</i> cytotoxicity studies showed a significant reduction in IC<sub>50</sub> values on MDA-MB-231 cell lines. <b>Conclusion:</b> We report a novel strategy of repurposing well-known drugs and encapsulating them into SLNs as a promising drug-delivery system against breast cancer.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11321401/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17435889.2024.2364585","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/16 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: The study explores the synergistic potential of atorvastatin (ATR) and quercetin (QUER)- loaded solid lipid nanoparticles (SLN) in combating breast cancer. Materials & methods: SLNs were synthesized using a high-shear homogenization method and optimized using Box-Behnken design. The SLNs were characterized and evaluated for their in vitro anticancer activity. Results: The optimized SLN exhibited narrow size distribution (PDI = 0.338 ± 0.034), a particle size of 72.5 ± 6.5 nm, higher entrapment efficiency (<90%), sustained release and spherical surface particles. The in vitro cytotoxicity studies showed a significant reduction in IC50 values on MDA-MB-231 cell lines. Conclusion: We report a novel strategy of repurposing well-known drugs and encapsulating them into SLNs as a promising drug-delivery system against breast cancer.

利用方框-贝肯设计优化阿托伐他汀和槲皮素负载固体脂质纳米颗粒。
目的:本研究探讨了阿托伐他汀(ATR)和槲皮素(QUER)负载型固体脂质纳米颗粒(SLN)在抗击乳腺癌方面的协同潜力。材料与方法:采用高剪切匀浆法合成 SLN,并采用 Box-Behnken 设计法进行优化。对固体脂质纳米粒子进行了表征,并评估了其体外抗癌活性。结果:优化后的 SLN 粒径分布窄(PDI = 0.338 ± 0.034),粒径为 72.5 ± 6.5 nm,包埋效率更高(体外细胞毒性研究显示,MDA-MB-231 细胞系的 IC50 值显著降低)。结论我们报告了一种新的策略,即重新利用知名药物并将其封装到 SLNs 中,作为一种很有前景的抗乳腺癌给药系统。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信